113 related articles for article (PubMed ID: 9859988)
1. p53 polymorphism and risk of cervical cancer.
Josefsson AM; Magnusson PK; Ylitalo N; Quarforth-Tubbin P; Pontén J; Adami HO; Gyllensten UB
Nature; 1998 Dec; 396(6711):531; author reply 532. PubMed ID: 9859988
[No Abstract] [Full Text] [Related]
2. p53 polymorphism and risk of cervical cancer.
Hildesheim A; Schiffman M; Brinton LA; Fraumeni JF; Herrero R; Bratti MC; Schwartz P; Mortel R; Barnes W; Greenberg M; McGowan L; Scott DR; Martin M; Herrera JE; Carrington M
Nature; 1998 Dec; 396(6711):531-2. PubMed ID: 9859989
[No Abstract] [Full Text] [Related]
3. Papillomavirus and p53.
zur Hausen H
Nature; 1998 May; 393(6682):217. PubMed ID: 9607756
[No Abstract] [Full Text] [Related]
4. [Polymorphism in codon 72 of the p53 gene and cervico-uterine cancer risk in Mexico].
Suárez-Rincón AE; Morán-Moguel MC; Montoya-Fuentes H; Gallegos-Arreola MP; Sánchez-Corona J
Ginecol Obstet Mex; 2002 Jul; 70():344-8. PubMed ID: 12221910
[TBL] [Abstract][Full Text] [Related]
5. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer.
Storey A; Thomas M; Kalita A; Harwood C; Gardiol D; Mantovani F; Breuer J; Leigh IM; Matlashewski G; Banks L
Nature; 1998 May; 393(6682):229-34. PubMed ID: 9607760
[TBL] [Abstract][Full Text] [Related]
6. p53 polymorphism and risk of cervical cancer.
Helland A; Langerød A; Johnsen H; Olsen AO; Skovlund E; Børresen-Dale AL
Nature; 1998 Dec; 396(6711):530-1; author reply 532. PubMed ID: 9859987
[No Abstract] [Full Text] [Related]
7. HPV 16-E6-mediated degradation of intrinsic p53 is compensated by upregulation of p53 gene expression in normal cervical keratinocytes.
Kawamata Y; Mitsuhashi A; Unno Y; Kado S; Shino Y; Uesugi K; Eguchi O; Ishii J; Seki K; Sekiya S; Shirasawa H
Int J Oncol; 2002 Sep; 21(3):561-7. PubMed ID: 12168100
[TBL] [Abstract][Full Text] [Related]
8. Integration status of virus DNA and p53 codon 72 polymorphism in human papillomavirus type 16 positive cervical cancers.
Szarka K; Veress G; Juhász A; Kónya J; Sápy T; Soós G; Hernádi Z; Gergely L
Anticancer Res; 2000; 20(3B):2161-7. PubMed ID: 10928171
[TBL] [Abstract][Full Text] [Related]
9. [Correlation between P53 codon 72 polymorphism and tumorigenesis of cervical cancer].
Li CY; Liu JH; Huang BJ
Ai Zheng; 2004 Nov; 23(11 Suppl):1396-9. PubMed ID: 15566643
[TBL] [Abstract][Full Text] [Related]
10. Ethnic variation of the P53 codon 72 polymorphism, HPV persistence, and cervical cancer risk.
Inserra P; Abrahamsen M; Papenfuss M; Giuliano AR
Int J STD AIDS; 2003 Dec; 14(12):800-4. PubMed ID: 14678586
[TBL] [Abstract][Full Text] [Related]
11. Induction of the p53-target gene GADD45 in HPV-positive cancer cells.
Butz K; Whitaker N; Denk C; Ullmann A; Geisen C; Hoppe-Seyler F
Oncogene; 1999 Apr; 18(14):2381-6. PubMed ID: 10327059
[TBL] [Abstract][Full Text] [Related]
12. TP53 polymorphism, HPV infection, and risk of cervical cancer.
Klug SJ; Wilmotte R; Santos C; Almonte M; Herrero R; Guerrero I; Caceres E; Peixoto-Guimaraes D; Lenoir G; Hainaut P; Walboomers JM; Muñoz N
Cancer Epidemiol Biomarkers Prev; 2001 Sep; 10(9):1009-12. PubMed ID: 11535556
[TBL] [Abstract][Full Text] [Related]
13. Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference.
Jiang M; Milner J
Oncogene; 2002 Sep; 21(39):6041-8. PubMed ID: 12203116
[TBL] [Abstract][Full Text] [Related]
14. Correspondence re: Ferguson AM, Svoboda-Newman SM, Frank TS: Analysis of human papillomavirus infection and molecular alterations in adenocarcinoma of the cervix. Mod Pathol 1:11-18, 1998.
Tenti P; Zappatore R; Carnevali L
Mod Pathol; 1999 Dec; 12(12):1192-3. PubMed ID: 10619275
[No Abstract] [Full Text] [Related]
15. The role of TP53 in Cervical carcinogenesis.
Tommasino M; Accardi R; Caldeira S; Dong W; Malanchi I; Smet A; Zehbe I
Hum Mutat; 2003 Mar; 21(3):307-12. PubMed ID: 12619117
[TBL] [Abstract][Full Text] [Related]
16. [Risk factors for cervico-uterine cancer associated to HPV: p53 codon 72 polymorphism in women attending hospital care].
Sifuentes Alvarez A; Reyes Romero M
Ginecol Obstet Mex; 2003 Jan; 71():12-5. PubMed ID: 12708345
[TBL] [Abstract][Full Text] [Related]
17. [Ha-ras and p53 gene mutations scanned by PCR-SSCP in premalignant and malignant lesions of the uterine cervix associated with human papillomavirus].
Alonio LV; Dalbert D; Picconi MA; Cervantes Vazquez G; García Carrancá A; Distefano AL; Mural J; Bartt O; Bazan G; Teyssie AR
Medicina (B Aires); 2000; 60(6):895-901. PubMed ID: 11436698
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of E6 induced degradation of p53 is not sufficient for stabilization of p53 protein in cervical tumour derived cell lines.
Mantovani F; Banks L
Oncogene; 1999 Jun; 18(22):3309-15. PubMed ID: 10362351
[TBL] [Abstract][Full Text] [Related]
19. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner.
López-Ocejo O; Viloria-Petit A; Bequet-Romero M; Mukhopadhyay D; Rak J; Kerbel RS
Oncogene; 2000 Sep; 19(40):4611-20. PubMed ID: 11030150
[TBL] [Abstract][Full Text] [Related]
20. Determination of p53-mediated transactivational ability in radiation-treated cervical cancer.
Oka A; Harima Y; Harima K; Ostapenko VV; Tanaka Y; Ohnishi T; Sawada S
Cancer Detect Prev; 2000; 24(3):275-82. PubMed ID: 10975290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
